NCT07652242
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Recruiting
PHASE1Ages 18+InterventionalTreatmentImmunomic Therapeutics, Inc.
~60 participants
Updated 2026-09-10 on ClinicalTrials.gov
What's tested:ITI-5000 mRNA VaccinePembrolizumabOlaparibCapecitabineITI-5000 MTD (Maximum Tolerated Dose)
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0
Measured over 21-28 days after the first vaccination
Conditions
NCT07652242
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Sarah Cannon Research Institute
Nashville, Tennesseestudy coordinator listed
Recruiting
START Midwest
Grand Rapids, Michiganstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.021-28 days after the first vaccination